Shares of Molecular Partners AG (MOLN) open at CHF 25.00

Today, the shares of Molecular Partners AG were traded for the first time under the “Main Standard” of SIX Swiss Exchange, opening at CHF 25.00. This corresponds to a total market capitalization of around CHF 482.0 million.

The issued share capital of Molecular Partners now comprises 19,300,310 registered shares (before exercise of the over-allotment option) with a nominal value of CHF 0.10 per share. Molecular Partners issued 4,307,000 new registered shares in the offering, thereby raising approx. CHF 96.5 million in gross proceeds (before exercise of the over-allotment option). In addition to the newly issued shares, 93,000 registered shares were sold by existing shareholders in the base offering. Furthermore, Molecular Partners has granted the underwriters an over-allotment option of up to 660,000 additional registered shares, which can be exercised within 30 days after the first day of trading in shares of Molecular Partners.

Molecular Partners is a clinical-stage biopharmaceutical company that is developing a new powerful class of therapies known as DARPins™. DARPins™ are potent, specific and versatile small protein therapies which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to enable a “multi-benefit” approach to treatment which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins™ have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. Its most advanced product candidate is abicipar pegol, for which the company's partner Allergan plans to initiate a Phase III clinical trial in wet AMD in 2015. The company has ongoing research and development partnerships with leading pharmaceutical companies including Allergan, Roche and Janssen and is backed by established biotech investors.
Should you have any questions, please feel free to contact Stephan Meier, Media Relations.

Phone: +41 58 399 3290  
Fax: +41 58 499 2710  
E-mail: pressoffice@six-group.com

SIX Swiss Exchange

SIX Swiss Exchange is the most important independent exchange in Europe. We connect companies from around the world with international investors and trading participants and create particularly market-oriented framework conditions for listing and trading in our highly liquid segments Equities, Bonds, ETFs, ETPs and Structured Products and Warrants. SIX Swiss Exchange is an ideal listing location for companies of every origin, size and sector. With the world’s fastest trading technology X-stream INET as well as the most advanced connectivity options, we offer our trading participants excellent trading conditions. We maintain a close dialogue with both our domestic and foreign customers, working intensively with them to create optimal conditions for their success. Furthermore, we offer them access to a strong global network.

www.six-swiss-exchange.com

SIX

SIX operates Switzerland’s financial market infrastructure and offers on a global scale comprehensive services in the areas of securities trading, clearing and settlement, as well as financial information and payment transactions. The company is owned by its users (approximately 140 banks of various size and orientation) and, with its workforce of more than 3,700 employees and presence in 23 countries, generated an operating income of 1.58 billion Swiss francs and a Group net profit of CHF 210.2 million in 2013.

www.six-group.com